Skip to main content

Phathom Pharmaceuticals, Inc.

PHAT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001783183

No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of PHAT: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders8382−1
Shares28.6M25.7M−2.92M (−10.2%)
Value$562.0M$349.1M−$212.8M (−37.9%)

New holders (12)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to PHAT in Q1 2022
InstitutionSharesValue% of portfolio
Frazier Life Sciences Management, L.P.5,827,415$79.3M6.76%
MPM Oncology Impact Management LP193,326$2.63M0.71%
Penn Mutual Asset Management, LLC86,940$1.18M1.37%
Barclays PLC6,967$94.0K0.00%
Amalgamated Bank3,309$45.0K0.00%
Amalgamated Financial Corp.3,309$45.0K0.00%
FMR LLC483$7.00K0.00%
Lindbrook Capital, LLC137$2.00K0.00%
Kayne Anderson Rudnick Investment Management LLC39$1.00K0.00%
Signaturefd, LLC101$1.00K0.00%
IFP Advisors, Inc56$1.00K0.00%
CWM, LLC36$00.00%

Sold out (13)

Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of PHAT in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Frazier Management LLC5,827,415$114.6M
Ra Capital Management, L.P.3,115,008$61.3M
Artal Group S.A.200,000$3.93M
Jacobs Levy Equity Management, Inc165,642$3.26M
Laurion Capital Management LP50,000$984.0K
Pictet Asset Management SA16,197$319.0K
Citadel Advisors LLC11,466$226.0K
Manufacturers Life Insurance Company, The11,443$225.0K
UBS Group AG1,329$26.0K
Amplius Wealth Advisors, LLC660$12.0K
HM Payson & Co111$2.00K
Quadrant Capital Group LLC49$1.00K
Captrust Financial Advisors20$0